Compare KVYO & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KVYO | MMED |
|---|---|---|
| Founded | 2012 | 1983 |
| Country | United States | United States |
| Employees | 2368 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.1B |
| IPO Year | 2023 | 2026 |
| Metric | KVYO | MMED |
|---|---|---|
| Price | $15.02 | $10.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 10 |
| Target Price | ★ $34.48 | $22.56 |
| AVG Volume (30 Days) | ★ 6.1M | 582.9K |
| Earning Date | 05-05-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.29 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $1,234,019,000.00 | N/A |
| Revenue This Year | $24.47 | $15.99 |
| Revenue Next Year | $19.66 | $10.00 |
| P/E Ratio | $485.83 | ★ N/A |
| Revenue Growth | ★ 31.63 | N/A |
| 52 Week Low | $13.53 | $10.65 |
| 52 Week High | $36.76 | $17.86 |
| Indicator | KVYO | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 38.30 | 33.75 |
| Support Level | N/A | N/A |
| Resistance Level | $21.34 | $15.80 |
| Average True Range (ATR) | 1.13 | 0.69 |
| MACD | -0.41 | -0.01 |
| Stochastic Oscillator | 14.91 | 16.75 |
Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service, and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically, the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.